Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Open accessAbstract
This study investigated the effect of subcutaneously administered oxyntomodulin on body weight in healthy overweight and obese volunteers. Participants self-administered saline or oxyntomodulin subcutaneously in a randomized, double-blind, parallel-group protocol. Injections were self-administered for 4 weeks, three times daily, 30 min before each meal. The volunteers were asked to maintain their regular diet and level of physical exercise during the study period. Subjects’ body weight, energy intake, and levels of adipose hormones were assessed at the start and end of the study. Body weight was reduced by 2.3 ± 0.4 kg in the treatment group over the study period compared with 0.5 ± 0.5 kg in the control group (P = 0.0106). On average, the treatment group had an additional 0.45-kg weight loss per week. The treatment group demonstrated a reduction in leptin and an increase in adiponectin. Energy intake by the treatment group was significantly reduced by 170 ± 37 kcal (25 ± 5%) at the initial study meal (P = 0.0007) and by 250 ± 63 kcal (35 ± 9%) at the final study meal (P = 0.0023), with no change in subjective food palatability. Oxyntomodulin treatment resulted in weight loss and a change in the levels of adipose hormones consistent with a loss of adipose tissue. The anorectic effect was maintained over the 4-week period. Oxyntomodulin represents a potential therapy for obesity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Oxyntomodulin activates the glucagon receptor and GLP-1 receptor and promotes weight loss through elevated energy expenditure and decreased energy intake in humans.
“Oxyntomodulin activates the glucagon receptor and GLP-1 receptor and promotes weight loss through elevated energy expenditure and decreased energy intake in humans (Wynne et al, 2005(Wynne et al, , 2006)).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wynne et al, 2005
The Results and Discussion report weight loss and decreased energy intake in overweight and obese humans; the Discussion attributes the weight loss to reduced energy intake. Our copy does not establish that oxyntomodulin activates both the glucagon and GLP-1 receptors or that elevated energy expenditure contributed to the weight loss. Page numbers were not supplied for these passages. (LLM, conf=0.89)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.
Hedley, A. A., Ogden, C., Johnson, C. L., Carroll, M., Curtin, L. R., & Flegal, K. (2004) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.291.23.2847 · Cited by 4,670 · see citing works
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · see citing works
Self-citationGut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · see citing works
Self-citationGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY <sub>3–36</sub>
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · see citing works
Self-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416 · see citing works
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · see citing works
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works
Food Fails to Suppress Ghrelin Levels in Obese Humans
English, P., Ghatei, M. A., Malik, I., Bloom, S. R., & Wilding, J. P. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8738 · Cited by 535 · see citing works
Self-citationOxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 473 · see citing works
Self-citationPeripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in Rats
Dakin, C. L., Small, C. J., Batterham, R. L., Neary, N. M., Cohen, M. A., Patterson, M., Ghatei, M. A., & Bloom, S. R. (2004) · Endocrinology · doi:10.1210/en.2003-1338 · Cited by 342 · see citing works
Self-citationEffect of peptide YY on gastric, pancreatic, and biliary function in humans
Adrian, T. E., Savage, A. P., Sagor, G. R., Allen, J. M., Bacarese-Hamilton, A. J., Tatemoto, K., Polak, J. M., & Bloom, S. R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90442-1 · Cited by 276 · see citing works
Self-citationGhatei, M. A., UTTENTHAL, L. O., Christofides, N. D., Bryant, M. G., & Bloom, S. R. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-3-488 · Cited by 164 · see citing works
Self-citationDl, S., Scopinaro, N., & Bloom, S. R. (1981) · PubMed · Cited by 162 · see citing works
Self-citationLife events, emotional eating and change in body mass index.
van Strien, T., Rookus, M. A., Bergers, G. P. A., Frijters, J. E. R., & Defares, P. B. (1986) · PubMed · Cited by 109 · see citing works
Plasma Enteroglucagon after Jejunoileal Bypass with 3:1 or 1:3 Jejunoileal Ratio
Holst, J. J., Sørensen, T. I. A., Andersen, A. N., STADIL, F., Andersen, B., Lauritsen, K. B., & Klein, H. C. (1979) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365527909179871 · Cited by 95 · see citing works
Eating behavior, personality traits and body mass in women
Van Strien, T., Frijters, J. E. R., Roosen, R. F. M., Knuiman-Hijl, W. J. H., & Defares, P. B. (1985) · Addictive Behaviors · doi:10.1016/0306-4603(85)90029-2 · Cited by 89 · see citing works
PRESCRIPTION OF DIABETIC DIETS IN THE 1980s
Lean, M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91111-6 · Cited by 76 · see citing works
Finer, N. (2002) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2002.0231 · Cited by 71 · see citing works
Murphy, K. G., Cr, A., Mahmoudi, M., Hunter, R. G., Gardiner, J., Rossi, M., Stanley, S., Ghatei, M. A., Kuhar, M. J., & Bloom, S. R. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1660659 · Cited by 71 · see citing works
Self-citationEDWARDS, C. M. B., TODD, J. F., Ghatei, M. A., & Bloom, S. R. (1998) · Clinical Science · doi:10.1042/cs0950719 · Cited by 57 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · see citing works
Gastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216 · see citing works
Gut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778 · see citing works
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745 · see citing works
“Though small clinical studies have suggested that oxyntomodulin may be effective for weight loss (Wynne et al., 2005), clinical studies of dual GLP1R/GCGR agonists or triple GLP1R/ GIPR/GCGR have not been reported as of this writing.”
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647 · see citing works
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641 · see citing works
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 611 · see citing works
Gut Hormones and Appetite Control
Wren, A., & Bloom, S. R. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.048 · Cited by 434 · see citing works
Self-citationThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · see citing works
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409 · see citing works
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363 · see citing works
Self-citationGastrointestinal hormones regulating appetite
Chaudhri, O. B., Small, C. J., & Bloom, S. R. (2006) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2006.1856 · Cited by 347 · see citing works
Self-citationSatiation, satiety and their effects on eating behaviour
Benelam, B. (2009) · Nutrition Bulletin · doi:10.1111/j.1467-3010.2009.01753.x · Cited by 338 · see citing works
Gastrointestinal Satiety Signals
Chaudhri, O. B., Salem, V., Murphy, K. G., & Bloom, S. R. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100506 · Cited by 340 · see citing works
Self-citationThe role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Pοlyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277 · see citing works
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258 · see citing works
Self-citationThe effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
Meek, C. L., Lewis, H. B., Reimann, F. M., Gribble, F. M., & Park, A. J. (2015) · Peptides · doi:10.1016/j.peptides.2015.08.013 · Cited by 268 · see citing works
Self-citationCrespo, C. S., Cachero, A. P., Puebla, L., Barrios, V., & Arilla, E. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00058 · Cited by 260 · see citing works
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248 · see citing works
Gut Peptides in the Regulation of Food Intake and Energy Homeostasis
Murphy, K. G., Dhillo, W. S., & Bloom, S. R. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0028 · Cited by 243 · see citing works
Self-citationHenderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240 · see citing works
Lockie, S. H., Heppner, K. M., Chaudhary, N., Chabenne, J. R., Morgan, D. A., Veyrat‐Durebex, C., Ananthakrishnan, G., Rohner‐Jeanrenaud, F., Drucker, D. J., DiMarchi, R. D., et al. (2012) · Diabetes · doi:10.2337/db11-1556 · Cited by 238 · see citing works
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232 · see citing works
Biologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 230 · see citing works
Appetite regulation and weight control: the role of gut hormones
Perry, B., & Wang, Y. (2012) · Nutrition and Diabetes · doi:10.1038/nutd.2011.21 · Cited by 214 · see citing works
Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220 · see citing works
The obesity pipeline: current strategies in the development of anti-obesity drugs
Cooke, D., & Bloom, S. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 212 · see citing works
Self-citationThe role of gut hormones in the regulation of body weight and energy homeostasis
Karra, E., & Batterham, R. L. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.010 · Cited by 210 · see citing works
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195 · see citing works
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199 · see citing works
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191 · see citing works
Obesity: Current and potential pharmacotherapeutics and targets
Narayanaswami, V., & Dwoskin, L. P. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 184 · see citing works
The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
Bliss, E., & Whiteside, E. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00900 · Cited by 188 · see citing works
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175 · see citing works
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174 · see citing works
Appetite signaling: From gut peptides and enteric nerves to brain
Näslund, E. B., & Hellström, P. M. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.017 · Cited by 173 · see citing works
Bowels control brain: gut hormones and obesity
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.93 · Cited by 171 · see citing works
Self-citationMalnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment
Nicolini, A., Ferrari, P., Masoni, M. C., Fini, M., Pagani, S., Giampietro, O., & Carpi, A. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.08.005 · Cited by 170 · see citing works
The role of the gut/brain axis in modulating food intake
Sam, A. H., Troke, R., Tan, T., & Bewick, G. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.008 · Cited by 168 · see citing works
Potential Hormone Mechanisms of Bariatric Surgery
Dimitriadis, G. K., Randeva, M. S., & Miras, A. D. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0276-5 · Cited by 168 · see citing works
Pharmacological Treatment of the Overweight Patient
Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 167 · see citing works
Tillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164 · see citing works
Gastrointestinal targets of appetite regulation in humans
Delzenne, N. M., Blundell, J. E., Brouns, F. J. P. H., Cunningham, K., de Graaf, K. C., Erkner, A., Lluch, A., Mars, M., Peters, H. P. F., & Westerterp‐Plantenga, M. S. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00707.x · Cited by 162 · see citing works
Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones
El‐Salhy, M., Hatlebakk, J. G., & Hausken, T. (2019) · Nutrients · doi:10.3390/nu11081824 · Cited by 146 · see citing works
Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149 · see citing works
Emerging Therapeutic Strategies for Obesity
Foster‐Schubert, K. E., & Cummings, D. E. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0041 · Cited by 139 · see citing works
Pharmacological management of appetite expression in obesity
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 142 · see citing works
Minireview: Glucagon in Stress and Energy Homeostasis
Jones, B. J., Tan, T., & Bloom, S. R. (2012) · Endocrinology · doi:10.1210/en.2011-1979 · Cited by 140 · see citing works
Self-citationGut hormones: Implications for the treatment of obesity
Neary, M. T., & Batterham, R. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.005 · Cited by 138 · see citing works
Obesity and the role of gut and adipose hormones in female reproduction
Gosman, G. G., Katcher, H. I., & Legro, R. S. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml024 · Cited by 137 · see citing works
Day, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science · doi:10.1002/bip.22072 · Cited by 133 · see citing works
Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R., & Hennige, A. M. (2024) · Diabetologia · doi:10.1007/s00125-023-06053-9 · Cited by 138 · see citing works
Laferrère, B., Swerdlow, N. J., Bawa, B., Arias, S., Bose, M., Oliván, B., Teixeira, J. A., McGinty, J., & Rother, K. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2767 · Cited by 132 · see citing works
Jørgensen, R., Kubale, V., Vrecl, M., Schwartz, T. W., & Elling, C. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120006 · Cited by 132 · see citing works
Microbial regulation of GLP-1 and L-cell biology
Greiner, T. U., & Bäckhed, F. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.012 · Cited by 134 · see citing works
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 130 · see citing works
Latest approaches for the treatment of obesity
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132 · see citing works
How functional foods play critical roles in human health
Pang, G., Xie, J., Chen, Q., & Zhi-he, H. (2012) · Food Science and Human Wellness · doi:10.1016/j.fshw.2012.10.001 · Cited by 129 · see citing works
Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 126 · see citing works
The future role of gut hormones in the treatment of obesity
Troke, R., Tan, T., & Bloom, S. R. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 126 · see citing works
Self-citationAppetite Regulation: An Overview
Dhillo, W. S. (2007) · Thyroid · doi:10.1089/thy.2007.0018 · Cited by 126 · see citing works
Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity
Miller, G. D. (2017) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617716376 · Cited by 126 · see citing works
Parker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123 · see citing works
Evers, S. S., Sandoval, D. A., & Seeley, R. J. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034423 · Cited by 118 · see citing works
Drug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115 · see citing works
Druce, M. R. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2005.073759 · Cited by 113 · see citing works
Field, B. C. T., Wren, A., Peters, V., Baynes, K., Martin, N. M., Patterson, M., Alsaraf, S., Amber, V., Wynne, K., Ghatei, M. A., et al. (2010) · Diabetes · doi:10.2337/db09-1859 · Cited by 113 · see citing works
Self-citationGut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 108 · see citing works
Behary, P., Tharakan, G., Αλεξιάδου, Κ., Johnson, N. A., Albrechtsen, N. J. W., Kenkre, J. S., Cuenco, J., Hope, D. C. D., Anyiam, O., Choudhury, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0449 · Cited by 112 · see citing works
Self-citationMedical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109 · see citing works
Diet in irritable bowel syndrome
El‐Salhy, M., & Gundersen, D. (2015) · Nutrition Journal · doi:10.1186/s12937-015-0022-3 · Cited by 111 · see citing works
Mechanisms responsible for excess weight loss after bariatric surgery
Ionut, V., & Bergman, R. N. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500536 · Cited by 105 · see citing works
Monteiro, M. P., & Batterham, R. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.053 · Cited by 104 · see citing works
Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids
Alhabeeb, H., AlFaiz, A., Kutbi, E., AlShahrani, D. A., Alsuhail, A., Alrajhi, S., Alotaibi, N., Alotaibi, K., Alamri, S. S., Alghamdi, S. A. A., et al. (2021) · Nutrients · doi:10.3390/nu13020481 · Cited by 109 · see citing works
The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin
Kosinski, J. R., Hubert, J. A., Carrington, P. E., Chicchi, G. G., Mu, J., Miller, C., Cao, J., Bianchi, E., Pessi, A., SinhaRoy, R., et al. (2012) · Obesity · doi:10.1038/oby.2012.67 · Cited by 106 · see citing works
The mechanisms of weight loss after bariatric surgery
Tadross, J. A., & le Roux, C. W. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.14 · Cited by 106 · see citing works
Valdecantos, M. P., Pardo, V., Ruiz, L., Castro‐Sánchez, L., Lanzón, B., Fernández‐Millán, E., García‐Monzón, C., Arroba, A. I., González‐Rodríguez, Á., Escrivá, F., et al. (2017) · Hepatology · doi:10.1002/hep.28962 · Cited by 100 · see citing works
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101 · see citing works
Changes in gut hormones after bariatric surgery
Vincent, R. P., & Le Roux, C. W. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03164.x · Cited by 100 · see citing works
Scott, W. R., & Batterham, R. L. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00038.2011 · Cited by 99 · see citing works
Gut hormones and appetite control
Hameed, S., Dhillo, W. S., & Bloom, S. R. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01492.x · Cited by 98 · see citing works
Self-citationEmerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102 · see citing works
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96 · see citing works
Is irritable bowel syndrome an organic disorder?
El‐Salhy, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.384 · Cited by 95 · see citing works
Seghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00649 · Cited by 92 · see citing works
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91 · see citing works
Hormonal Regulators of Appetite
Austin, J., & Marks, D. L. (2008) · International Journal of Pediatric Endocrinology · doi:10.1155/2009/141753 · Cited by 113 · see citing works
Neuropeptide Y and peptide YY: important regulators of energy metabolism
Nguyen, A., Herzog, H., & Sainsbury, A. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283422f0a · Cited by 90 · see citing works
Parkinson, J. R. C., Chaudhri, O. B., Kuo, Y., Field, B. C. T., Herlihy, A. H., Dhillo, W. S., Ghatei, M. A., Bloom, S. R., & Bell, J. D. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.09.047 · Cited by 89 · see citing works
Self-citationBagger, J. I., Holst, J. J., Hartmann, B., Andersen, B., Knop, F. K., & Vilsbøll, T. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2335 · Cited by 91 · see citing works
Gut–Brain Axis: Regulation of Glucose Metabolism
Heijboer, A. C., Pijl, H., van den Hoek, A. M., Havekes, L. M., Romijn, J. A., & Corssmit, E. P. M. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01492.x · Cited by 86 · see citing works
Chaudhri, O. B., Parkinson, J. R. C., Kuo, Y., Druce, M. R., Herlihy, A. H., Bell, J. D., Dhillo, W. S., Stanley, S. A., Ghatei, M. A., & Bloom, S. R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.033 · Cited by 87 · see citing works
Self-citationProglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential
Sinclair, E. M., & Drucker, D. J. (2005) · Physiology · doi:10.1152/physiol.00030.2005 · Cited by 87 · see citing works
Oxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86 · see citing works
Richards, P., Thornberry, N. A., & Pinto, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101175 · Cited by 88 · see citing works
The role of oxyntomodulin and peptide tyrosine–tyrosine (PYY) in appetite control
Wynne, K., & Bloom, S. R. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0318 · Cited by 84 · see citing works
Self-citationLeveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 82 · see citing works
Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Druce, M. R., MINNION, J. S., Field, B. C. T., Patel, S. R., Shillito, J. C., Tilby, M. J., Beale, K., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2008) · Endocrinology · doi:10.1210/en.2008-0828 · Cited by 84 · see citing works
Self-citationJouy, S. H., Mohan, S., Scichilone, G., Mostafa, A., & Mahmoud, A. M. (2024) · Biomedicines · doi:10.3390/biomedicines12092129 · Cited by 92 · see citing works
The hypothalamus, hormones, and hunger: alterations in human obesity and illness
Goldstone, A. P. (2006) · Progress in brain research · doi:10.1016/s0079-6123(06)53003-1 · Cited by 83 · see citing works
- Authors
- Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Department of Dietetics, Imperial College Faculty of Medicine, Hammersmith Hospital, London, U.K
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2005-08-01
- Volume
- 54
- Issue
- 8
- Pages
- 2390-2395
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2154497567
- Cited by
- 435
- References
- 21
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 17 · 2023: 24 · 2022: 10 · 2021: 24 · 2020: 22 · 2019: 16 · 2018: 26 · 2017: 17 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 31 · 2012: 26
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- oxyntomodulin, obesity, weight loss, subcutaneous administration, energy intake, leptin, adiponectin, adipose tissue, anorectic effect, palatability, appetite regulation
- MeSH terms
- Adipose Tissue, Adolescent, Adult, Blood Glucose, Body Composition, Energy Intake, Diet, Double-Blind Method, Eating, Glucagon-Like Peptides, Female, Humans, Injections, Subcutaneous, Insulin, Kinetics, Male, Middle Aged, Obesity, Self Administration, Weight Loss, Exercise, Leptin, Intercellular Signaling Peptides and Proteins, Adiponectin, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
